Ieq Capital LLC Purchases Shares of 148,901 Natera, Inc. $NTRA

Key Points

• Ieq Capital LLC acquired 148,901 Natera shares worth approximately $40.4 million in the second quarter, giving it a 0.10% stake. Institutional investors collectively own 99.90% of Natera.
• Analyst sentiment is favorable, with a consensus “Moderate Buy” rating and an average price target of $319.38; JPMorgan and RBC recently raised their targets to $360 and $350, respectively.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above estimates, while its adjusted loss of $0.47 per share narrowly beat expectations.

Ieq Capital LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 148,901 shares of the medical research company's stock, valued at approximately $40,419,000. Ieq Capital LLC owned 0.10% of Natera as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NTRA. Trust Co. of Vermont bought a new stake in Natera in the 2nd quarter valued at $26,000. Elevation Wealth Partners LLC bought a new position in Natera during the 2nd quarter worth about $30,000. Reflection Asset Management acquired a new stake in shares of Natera in the 4th quarter valued at about $29,000. Palladiem LLC acquired a new stake in shares of Natera in the 4th quarter valued at about $31,000. Finally, Bank of Jackson Hole Trust lifted its holdings in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank Of Canada upped their price objective on Natera from $275.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, August 7th. The Goldman Sachs Group assumed coverage on Natera in a research note on Friday, June 5th. They issued a "neutral" rating and a $245.00 target price on the stock. Wolfe Research began coverage on Natera in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Natera from $315.00 to $360.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Finally, Sanford C. Bernstein started coverage on shares of Natera in a report on Friday, June 26th. They issued an "outperform" rating and a $310.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $319.38.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares in the company, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the transaction, the chief financial officer directly owned 51,637 shares in the company, valued at $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 181,045 shares of company stock valued at $41,330,968. Corporate insiders own 5.05% of the company's stock.

Natera Price Performance

Natera stock opened at $332.03 on Friday. The company's 50-day moving average is $274.24 and its 200-day moving average is $229.39. The firm has a market capitalization of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $333.56.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the business posted ($0.74) EPS. Natera's revenue was up 37.7% on a year-over-year basis. As a group, analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source